Local Complications, Graft Thrombosis, Anastomotic Aneurysm, and Endovascular/Access Complication Rescue
Local vascular complications named by failure mode before rescue is chosen: graft thrombosis, anastomotic aneurysm, infection, pseudoaneurysm, and endovascular access disasters. The chapter frames the least morbid rescue that restores durable flow or seal for each failure pattern.
Consult corner: A bedside consult-style discussion focused on what the clinician should decide next and what not to overinterpret.
General medical education, not patient-specific advice.
Choose the hostsDefinition and presentation
Local vascular complications encompass failure of the reconstruction (thrombosis, endoleak, stenosis) or structural failure of the vessel and surrounding tissue (pseudoaneurysm, anastomotic aneurysm, wound breakdown). The clinical presentation determines the urgency of rescue, ranging from an asymptomatic finding on surveillance imaging to acute or chronic limb-threatening ischemia (CLTI).
In CLTI, the diagnosis combines ischemic rest pain or tissue loss with confirmed peripheral artery disease, staged by the Wound, Ischemia, and foot Infection (WIfI) system and mapped anatomically with the Global Limb Anatomic Staging System (GLASS) .
Post-revascularization failure modes are specific to the index procedure:
- Open infrainguinal bypass: stenosis, anastomotic defect, inflow or outflow disease, thrombosis, anastomotic pseudoaneurysm, and surgical-site infection.
- Endovascular aortic repair (EVAR): endoleak (Types I through IV), sac expansion, migration, limb kinking, junctional separation, and limb-graft occlusion .
- Percutaneous access: bleeding, iatrogenic pseudoaneurysm, arteriovenous fistula, closure-device failure, and access thrombosis .
Surveillance and diagnosis
Detecting a failing reconstruction before it occludes or ruptures is the point of surveillance.
After lower-extremity arterial revascularization, systematic clinical and duplex ultrasound surveillance is scheduled at 1, 3, and 6 months postoperatively, and annually thereafter . Preemptive operative or endovascular revision is indicated for hemodynamic deterioration or anatomically significant stenosis greater than 50% .
Following EVAR, surveillance tracks sac diameter, endoleak class, and device integrity. Contrast-enhanced CT angiography at 1 month sets the baseline; with no endoleak and no sac enlargement, imaging repeats at 12 months and then converts to annual color-duplex ultrasound, reserving CTA for a new or persistent endoleak, sac growth >= 5 mm, or an abnormal duplex . Any endoleak or sac growth shortens the interval. Polytetrafluoroethylene (PTFE)-based endografts exhibit a higher prevalence of Type II endoleak within one year than polyester-based devices; this higher prevalence necessitates rigorous imaging but does not trigger intervention without concurrent sac growth . Post-EVAR endoleaks or suspected failures on surveillance require computed tomography angiography (CTA) or adjunct imaging to map the anatomy and differentiate high-pressure seal failures from stable reperfusion .
Prevention and medical management
Percutaneous access complications occur in 3% to 4% of peripheral vascular interventions, with female sex, increasing sheath size, antithrombotic exposure, and non-routine closure-device use serving as independent predictors . Ultrasound-guided percutaneous femoral artery access reduces hematoma, pseudoaneurysm, and arteriovenous fistula formation compared with landmark-guided puncture and is the standard of practice, especially in patients with obesity, scarring, or absent pulses .
Groin surgical-site infections convert an adequate reconstruction into prolonged morbidity. Transverse groin incisions yield fewer surgical-site infections and lymphoceles than vertical incisions in selected femoral artery exposures . Closed-incision negative pressure wound therapy provides a pooled reduction in surgical-site infections compared with standard dressings for high-risk patients undergoing arterial surgery with groin incisions .
Antithrombotic therapy following infrainguinal revascularization lowers graft thrombosis and major adverse limb events . In VOYAGER PAD, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily reduced the composite of acute limb ischemia, major amputation, myocardial infarction, ischemic stroke, and cardiovascular death compared with aspirin alone at three years, with a corresponding increase in ISTH major bleeding . Systemic anticoagulation does not improve primary patency overall but is associated with better secondary patency in prosthetic conduits to below-knee targets, at the cost of higher wound complication rates .
Intervention triggers and treatment choice
Reintervention decisions integrate limb stage, anatomy, bleeding risk, and the failure mode. For infrapopliteal CLTI requiring revascularization, BASIL-2 demonstrated better amputation-free survival with a best-endovascular-first strategy than a vein-bypass-first strategy, driven primarily by differences in mortality . The earlier BASIL-1 data established foundational boundaries for severe limb ischemia; strategy selection must align with patient comorbidity, available conduit, and anatomic complexity .
Putting the rescue decision in order
- Name the failure mode: failing-but-patent bypass, acute graft occlusion, iatrogenic or anastomotic pseudoaneurysm, or endoleak.
- Stage the limb threat and screen for thrombolysis contraindications and bleeding risk . Stage acute occlusion by the Rutherford categories: I viable with no immediate threat; IIa marginally threatened and salvageable if promptly treated, with audible venous Doppler and minimal or no sensory loss; IIb immediately threatened and salvageable only with immediate revascularisation, with rest pain, sensory loss beyond the toes, and inaudible arterial Doppler; III irreversible, with profound sensory loss and paralysis, committing the limb to primary amputation. Catheter-directed thrombolysis suits categories I to IIa, IIb demands immediate open or mechanical revascularisation, and III mandates amputation .
- For acute occlusion, choose catheter-directed thrombolysis when the limb tolerates the time to reperfusion and lysis is not contraindicated, and urgent open thrombectomy when ischemia is severe or lysis is contraindicated .
- Match pseudoaneurysm rescue to neck morphology (thrombin injection versus surgical repair) and endoleak rescue to type .
- Treat the causative lesion, confirm inflow and outflow, and resume a surveillance interval matched to the repair.
Catheter-directed thrombolysis for acute lower-extremity bypass graft occlusion yields 89% one-month and 75% twelve-month amputation-free survival . STILE randomised catheter-directed lysis against surgery for non-embolic native and graft limb ischaemia and found no difference in death or major amputation; lysis reduced the magnitude of planned surgery and favoured symptom duration under 14 days, while surgery was superior beyond 14 days . TOPAS compared recombinant urokinase with primary surgery and gave similar amputation-free survival at 6 to 12 months with fewer subsequent open surgical procedures after lysis . Contraindications include stroke within 2 months, active bleeding, intracranial tumor, or systemic coagulopathy.
Type II endoleaks have a heterogeneous natural history, with roughly one-third resolving spontaneously, which supports observation until the sac grows .
Anatomic variants and specialized reconstructions
Endovascular limb-graft occlusion is strongly associated with hostile iliac anatomy, limb oversizing, and distal landing in a caliber-mismatched external iliac artery. Occlusion is managed via endovascular thrombolysis followed by adjunctive bare-metal stenting when anatomy permits .
During aortoiliac aneurysm repair, iliac branch devices are used to preserve hypogastric flow and prevent buttock claudication or pelvic ischemia, showing established midterm technical success and branch patency .
In zone-2 thoracic endovascular aortic repair (TEVAR), left subclavian artery revascularization is performed to mitigate the risk of stroke and spinal cord ischemia. Revascularization options include surgical bypass, surgical transposition, and endovascular strategies .
Areas of controversy
The durability of covered stent-graft repair for anastomotic femoral pseudoaneurysms remains unsettled; although technically feasible and advantageous in a hostile or previously infected groin, concern over late flexion-zone failure and reinfection prevents its substitution for the open-repair reference standard in anatomically favorable patients .
The routine application of closed-incision negative pressure therapy across all vascular groin incisions is debated; meta-analytic evidence primarily supports its selective deployment in high-risk patients to reduce surgical-site infections, rather than universal adoption .
The optimal revascularization strategy for severe limb ischemia is a persistent subject of interpretation. The BASIL-1 and BASIL-2 trials highlight differing endpoints; the survival advantage observed with an endovascular-first approach in BASIL-2 was driven by baseline cardiovascular comorbidity rather than superior procedural durability, necessitating ongoing individualized assessment .
References
- 1.
- 2.
- 3.
- 4.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. 2018.PubMed-indexed articleClinical practice guideline2017
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. 2018. doi:10.1093/eurheartj/ehx095.
- 5.2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024.PubMed-indexed articleClinical practice guideline2024
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024. doi:10.1161/CIR.0000000000001251. PMID:38743805.
- 6.
- 7.
- 8.Prevalence of type II endoleak after elective endovascular aneurysm repair with polytetrafluoroethylene- or polyester-based endografts. Journal of vascular surgery. 2024.PubMed-indexed article2024
Prevalence of type II endoleak after elective endovascular aneurysm repair with polytetrafluoroethylene- or polyester-based endografts. Journal of vascular surgery. 2024. doi:10.1016/j.jvs.2023.09.019.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency. Journal of vascular surgery. 2017.PubMed-indexed article2017
Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency. Journal of vascular surgery. 2017. doi:10.1016/j.jvs.2016.12.141.
- 20.A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2). Lancet. 2023.PubMed-indexed articleRandomized controlled trial2023
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2). Lancet. 2023. doi:10.1016/s0140-6736(23)00462-2
- 21.
- 22.
- 23.
- 24.Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection. Angiology. 2007.PubMed-indexed article2007
Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection. Angiology. 2007. doi:10.1177/0003319706294608.
- 25.
- 26.Non-Surgical treatment Versus Surgery for Iatrogenic Femoral Artery Pseudoaneurysms: Systematic Review and Meta-Analysis. Front Surg. 2022.PubMed-indexed articleMeta-analysis / systematic review2022
Non-Surgical treatment Versus Surgery for Iatrogenic Femoral Artery Pseudoaneurysms: Systematic Review and Meta-Analysis. Front Surg. 2022. doi:10.3389/fsurg.2022.905701. PMID:36211300.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.Type II Endoleak after Endovascular Aneurysm Repair: Natural History and Treatment Outcomes. Annals of vascular surgery. 2017.PubMed-indexed article2017
Type II Endoleak after Endovascular Aneurysm Repair: Natural History and Treatment Outcomes. Annals of vascular surgery. 2017. doi:10.1016/j.avsg.2017.04.029.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.Wanhainen A, Van Herzeele I, Bastos Goncalves F, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192-331.PubMed-indexed article2024
Wanhainen A, Van Herzeele I, Bastos Goncalves F, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192-331. doi:10.1016/j.ejvs.2023.11.002.
- 42.Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.e2.PubMed-indexed article2018
Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.e2. doi:10.1016/j.jvs.2017.10.044.
- 43.Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-538.PubMed-indexed article1997
Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-538. doi:10.1016/S0741-5214(97)70045-4.
- 44.Bjorck M, Earnshaw JJ, Acosta S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020;59(2):173-218.PubMed-indexed article2020
Bjorck M, Earnshaw JJ, Acosta S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020;59(2):173-218. doi:10.1016/j.ejvs.2019.09.006.
- 45.Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338(16):1105-1111.PubMed-indexed article1998
Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338(16):1105-1111. doi:10.1056/NEJM199804163381603.
- 46.The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220(3):251-268.PubMed-indexed article1994
The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220(3):251-268. doi:10.1097/00000658-199409000-00003.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.